Mitochondrial interference by anti-HIV drugs: Mechanisms beyond Pol-γ inhibition

Trends in Pharmacological Sciences

Volumn 32, Issue 12, 2011, Pages 715-725

  Apostolova, Nadezda ^a,b   Blas García, Ana ^a,b   Esplugues, Juan V ^a,b,c  

^a UNIVERSITY OF VALENCIA   (Spain)

^b INSTITUTO DE SALUD CARLOS III   (Spain)

^c Unidad Mixta de Neurorregeneración   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; AMPRENAVIR; ATAZANAVIR; DNA DIRECTED DNA POLYMERASE GAMMA; EFAVIRENZ; EMTRICITABINE; INDINAVIR; LOPINAVIR; MITOCHONDRIAL PROTEIN; MITOCHONDRIAL RNA; NELFINAVIR; NEVIRAPINE; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; PROTEINASE INHIBITOR; REACTIVE OXYGEN METABOLITE; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; ZIDOVUDINE;

CELL METABOLISM; DRUG INHIBITION; ENZYME INHIBITION; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MITOCHONDRION; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; REVIEW; SIGNAL TRANSDUCTION;

ANIMALS; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; DNA-DIRECTED DNA POLYMERASE; HUMANS; MITOCHONDRIA; MITOCHONDRIAL DISEASES; REVERSE TRANSCRIPTASE INHIBITORS;

EID: 81755173578     PISSN: 01656147     EISSN: 18733735     Source Type: Journal    
DOI: 10.1016/j.tips.2011.07.007     Document Type: Review

References (82)

1. S.M. Hammer Antiretroviral treatment of adult HIV infection: 2008 recommendations of the International AIDS Society-USA panel JAMA 300 2008 555 570
2. F. Petit Mitochondria are sensors for HIV drugs Trends Pharmacol. Sci. 26 2005 258 264 (Pubitemid 40603074)
3. E.R. Feeney, and P.W. Mallon Impact of mitochondrial toxicity of HIV-1 antiretroviral drugs on lipodystrophy and metabolic dysregulation Curr. Pharm. Des. 16 2010 3339 3351
4. A. Maagaard, and D. Kvale Long term adverse effects related to nucleoside reverse transcriptase inhibitors: clinical impact of mitochondrial toxicity Scand. J. Infect. Dis. 41 2009 808 817
5. M.R. Duchen, and G. Szabadkai Roles of mitochondria in human disease Essays Biochem. 47 2010 115 137
6. B.H. Cohen Pharmacologic effects on mitochondrial function Dev. Disabil. Res. Rev. 16 2010 189 199
7. D. Höschele Cell culture models for the investigation of NRTI-induced mitochondrial toxicity. Relevance for the prediction of clinical toxicity Toxicol. In Vitro 20 2006 535 546 (Pubitemid 43833270)
8. W. Lewis, and M.C. Dalakas Mitochondrial toxicity of antiviral drugs Nat. Med. 1 1995 417 422
9. N. Venhoff Mitochondrial toxicity of tenofovir, emtricitabine and abacavir alone and in combination with additional nucleoside reverse transcriptase inhibitors Antivir. Ther. 12 2007 1075 1085 (Pubitemid 350114988)
10. L. Enomoto Effect of nucleoside and nucleotide analog reverse transcriptase inhibitors on cell-mediated immune functions AIDS Res. Hum. Retroviruses 27 2011 47 55
11. H.C. Côté Possible ways nucleoside analogues can affect mitochondrial DNA content and gene expression during HIV therapy Antivir. Ther. 10 Suppl. 2 2005 M3 M11
12. D. Lebrecht Mitochondrial tubulopathy in tenofovir disoproxil fumarate-treated rats J. Acquir. Immune Defic. Syndr. 51 2009 258 263
13. J.J. Kohler Tenofovir renal toxicity targets mitochondria of renal proximal tubules Lab. Invest. 89 2009 513 519
14. H.C. Côté Exploring mitochondrial nephrotoxicity as a potential mechanism of kidney dysfunction among HIV-infected patients on highly active antiretroviral therapy Antivir. Ther. 11 2006 79 86
15. A. Blas-García Inhibition of mitochondrial function by efavirenz increases lipid content in hepatic cells Hepatology 52 2010 115 125
16. P.W. Mallon In vivo, nucleoside reverse-transcriptase inhibitors alter expression of both mitochondrial and lipid metabolism genes in the absence of depletion of mitochondrial DNA J. Infect. Dis. 191 2005 1686 1696 (Pubitemid 40656757)
17. C.M. Shikuma Mitochondrial oxidative phosphorylation protein levels in peripheral blood mononuclear cells correlate with levels in subcutaneous adipose tissue within samples differing by HIV and lipoatrophy status AIDS Res. Hum. Retroviruses 24 2008 1255 1262
18. S.H. Hosseini Targeted transgenic overexpression of mitochondrial thymidine kinase (TK2) alters mitochondrial DNA (mtDNA) and mitochondrial polypeptide abundance: transgenic TK2, mtDNA, and antiretrovirals Am. J. Pathol. 170 2007 865 874 (Pubitemid 47339356)
19. J.J. Kohler Murine cardiac mtDNA: effects of transgenic manipulation of nucleoside phosphorylation Lab. Invest. 89 2009 122 130
20. A. Igoudjil High concentrations of stavudine impair fatty acid oxidation without depleting mitochondrial DNA in cultured rat hepatocytes Toxicol. In Vitro 22 2008 887 898
21. M. Caron Contribution of mitochondrial dysfunction and oxidative stress to cellular premature senescence induced by antiretroviral thymidine analogues Antivir. Ther. 13 2008 27 38 (Pubitemid 351541671)
22. X. Wang Roles and mechanisms of human immunodeficiency virus protease inhibitor ritonavir and other anti-human immunodeficiency virus drugs in endothelial dysfunction of porcine pulmonary arteries and human pulmonary artery endothelial cells Am. J. Pathol. 174 2009 771 781
23. S. Viengchareun Mitochondrial toxicity of indinavir, stavudine and zidovudine involves multiple cellular targets in white and brown adipocytes Antivir. Ther. 12 2007 919 929 (Pubitemid 47492561)
24. L. Galluzzi Altered mitochondrial RNA production in adipocytes from HIV-infected individuals with lipodystrophy Antivir. Ther. 10 Suppl. 2 2005 M91 M99
25. G.A. McComsey Mitochondrial RNA and DNA alterations in HIV lipoatrophy are linked to antiretroviral therapy and not to HIV infection Antivir. Ther. 13 2008 715 722
26. M.J. Kim Mitochondrial DNA content, an inaccurate biomarker of mitochondrial alteration in human immunodeficiency virus-related lipodystrophy Antimicrob. Agents Chemother. 52 2008 1670 1676
27. M.L. Rodríguez de la Concepción Reverse transcriptase inhibitors alter uncoupling protein-1 and mitochondrial biogenesis in brown adipocytes Antivir. Ther. 10 2005 515 526 (Pubitemid 41059198)
28. L. Galluzzi Changes in mitochondrial RNA production in cells treated with nucleoside analogues Antivir. Ther. 10 2005 191 195 (Pubitemid 40767646)
29. H.C. Côté Perinatal exposure to antiretroviral therapy is associated with increased blood mitochondrial DNA levels and decreased mitochondrial gene expression in infants J. Infect. Dis. 198 2008 851 859
30. J.B. Rose, and I.R. Coe Physiology of nucleoside transporters: back to the future Physiol. (Bethesda) 23 2008 41 48
31. G.P. Leung, and C.M. Tse The role of mitochondrial and plasma membrane nucleoside transporters in drug toxicity Expert Opin. Drug Metab. Toxicol. 3 2007 705 718 (Pubitemid 351320638)
32. J.P. Guallar Altered expression of nucleoside transporter genes (SLC28 and SLC29) in adipose tissue from HIV-1-infected patients Antivir. Ther. 12 2007 853 863 (Pubitemid 47492555)
33. J.J. Kohler Tenofovir renal proximal tubular toxicity is regulated by OAT1 and MRP4 transporters Lab. Invest. 91 2011 852 858
34. R. Govindarajan Facilitated mitochondrial import of antiviral and anticancer nucleoside drugs by human equilibrative nucleoside transporter-3 Am. J. Physiol. Gastrointest. Liver Physiol. 296 2009 G910 G922
35. P. Domingo Association of thymidylate synthase gene polymorphisms with stavudine triphosphate intracellular levels and lipodystrophy Antimicrob. Agents Chemother. 55 2011 1428 1435
36. J.J. Kohler, and W. Lewis A brief overview of mechanisms of mitochondrial toxicity from NRTIs Environ. Mol. Mutagen. 48 2007 166 172 (Pubitemid 46536084)
37. N. Venhoff Oral uridine supplementation antagonizes the peripheral neuropathy and encephalopathy induced by antiretroviral nucleoside analogues AIDS 24 2010 345 352
38. G.A. McComsey Uridine supplementation in the treatment of HIV lipoatrophy: results of ACTG 5229 AIDS 24 2010 2507 2515
39. C.M. Bailey, and K.S. Anderson A mechanistic view of human mitochondrial DNA polymerase γ: providing insight into drug toxicity and mitochondrial disease Biochim. Biophys. Acta 1804 2010 1213 1222
40. B. Jiang HIV antiretroviral drug combination induces endothelial mitochondrial dysfunction and reactive oxygen species production, but not apoptosis Toxicol. Appl. Pharmacol. 224 2007 60 71 (Pubitemid 47404622)
41. K.C. Lund, and K.B. Wallace Adenosine 3′,5′-cyclic monophosphate (cAMP)-dependent phosphoregulation of mitochondrial complex I is inhibited by nucleoside reverse transcriptase inhibitors Toxicol. Appl. Pharmacol. 226 2008 94 106 (Pubitemid 350235579)
42. P.V. Nerurkar Sterol regulatory element-binding proteins and reactive oxygen species: potential role in highly-active antiretroviral therapy (HAART)-associated lipodystrophy Clin. Biochem. 34 2001 519 529 (Pubitemid 34014844)
43. F. Ciccosanti Proteomic analysis identifies prohibitin down-regulation as a crucial event in the mitochondrial damage observed in HIV-infected patients Antivir. Ther. 15 2010 377 390
44. C. Lagathu Some HIV antiretrovirals increase oxidative stress and alter chemokine, cytokine or adiponectin production in human adipocytes and macrophages Antivir. Ther. 12 2007 489 500 (Pubitemid 47041147)
45. J.J. Kohler Transgenic mitochondrial superoxide dismutase and mitochondrially targeted catalase prevent antiretroviral-induced oxidative stress and cardiomyopathy Lab. Invest. 89 2009 782 790
46. R.H. Lu Mitochondrial development and the influence of its dysfunction during rat adipocyte differentiation Mol. Biol. Rep. 37 2010 2173 2182
47. M. Caron Antiretroviral-related adipocyte dysfunction and lipodystrophy in HIV-infected patients: alteration of the PPARgamma-dependent pathways PPAR Res. 2009 2009 507141
48. C. Lagathu HIV antiretroviral treatment alters adipokine expression and insulin sensitivity of adipose tissue in vitro and in vivo Biochimie 87 2005 65 71 (Pubitemid 40298767)
49. K. Senior Growing old with HIV Lancet Infect. Dis. 5 2005 739
50. S. Desai, and A. Landay Early immune senescence in HIV disease Curr. HIV/AIDS Rep. 7 2010 4 10
51. M. Sievers Gene expression and immunohistochemistry in adipose tissue of HIV type 1-infected patients with nucleoside analogue reverse-transcriptase inhibitor-associated lipoatrophy J. Infect. Dis. 200 2009 252 262
52. V.G. Desai Nucleoside reverse transcriptase inhibitors (NRTIs)-induced expression profile of mitochondria-related genes in the mouse liver Mitochondrion 8 2008 181 195
53. M. Pinti Upregulation of nuclear-encoded mitochondrial LON protease in HAART-treated HIV-positive patients with lipodystrophy: implications for the pathogenesis of the disease AIDS 24 2010 841 850
54. D.A. Bota Downregulation of the human Lon protease impairs mitochondrial structure and function and causes cell death Free Radic. Biol. Med. 38 2005 665 677 (Pubitemid 40416862)
55. H.M. Wang Obtusilactone A and (-)-sesamin induce apoptosis in human lung cancer cells by inhibiting mitochondrial Lon protease and activating DNA damage checkpoints Cancer Sci. 101 2010 2612 2620
56. K. Kasashima Human prohibitin 1 maintains the organization and stability of the mitochondrial nucleoids Exp. Cell Res. 314 2008 988 996
57. I.F. Grigsby Downregulation of Gnas, Got2 and Snord32a following tenofovir exposure of primary osteoclasts Biochem. Biophys. Res. Commun. 391 2010 1324 1329
58. J.E. Gallant Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naive patients: a 3-year randomized trial JAMA 292 2004 191 201 (Pubitemid 38917996)
59. J.B. Purdy Decreased bone mineral density with off-label use of tenofovir in children and adolescents infected with human immunodeficiency virus J. Pediatr. 152 2008 582 584 (Pubitemid 351381047)
60. S. Chandra HIV-1 protease inhibitor induced oxidative stress suppresses glucose stimulated insulin release: protection with thymoquinone Exp. Biol. Med. (Maywood) 234 2009 442 453
61. S. Zhang Protease inhibitors used in the treatment of HIV+ induce beta-cell apoptosis via the mitochondrial pathway and compromise insulin secretion Am. J. Physiol. Endocrinol. Metab. 296 2009 E925 E935
62. W. Deng HIV protease inhibitors elicit volume-sensitive Cl- current in cardiac myocytes via mitochondrial ROS J. Mol. Cell Cardiol. 49 2010 746 752
63. M. Caron Human lipodystrophies linked to mutations in A-type lamins and to HIV protease inhibitor therapy are both associated with prelamin A accumulation, oxidative stress and premature cellular senescence Cell Death Differ. 14 2007 1759 1767 (Pubitemid 47423643)
64. G. Verucchi Ultrastructural liver mitochondrial abnormalities in HIV/HCV-coinfected patients receiving antiretroviral therapy J. Acquir. Immune Defic. Syndr. 35 2004 326 328 (Pubitemid 38280663)
65. T. Roumier HIV-1 protease inhibitors and cytomegalovirus vMIA induce mitochondrial fragmentation without triggering apoptosis Cell Death Differ. 13 2006 348 351 (Pubitemid 43102218)
66. A.D. Badley In vitro and in vivo effects of HIV protease inhibitors on apoptosis Cell Death Differ. 12 Suppl. 1 2005 924 931 (Pubitemid 41030607)
67. S.R. Vlahakis HIV protease inhibitors modulate apoptosis signaling in vitro and in vivo Apoptosis 12 2007 969 977 (Pubitemid 46653299)
68. A. Brüning The mitochondria-independent cytotoxic effect of nelfinavir on leukemia cells can be enhanced by sorafenib-mediated mcl-1 downregulation and mitochondrial membrane destabilization Mol. Cancer 9 2010 19
69. K.R. Manda Highly active antiretroviral therapy drug combination induces oxidative stress and mitochondrial dysfunction in immortalized human blood-brain barrier endothelial cells Free Radic. Biol. Med. 50 2011 801 810
70. A. Mukhopadhyay In vitro evidence of inhibition of mitochondrial protease processing by HIV-1 protease inhibitors in yeast: a possible contribution to lipodystrophy syndrome Mitochondrion 1 2002 511 518
71. A.A. Pilon Induction of apoptosis by a nonnucleoside human immunodeficiency virus type 1 reverse transcriptase inhibitor Antimicrob. Agents Chemother. 46 2002 2687 2691 (Pubitemid 34793489)
72. N. Apostolova Enhanced oxidative stress and increased mitochondrial mass during efavirenz-induced apoptosis in human hepatic cells Br. J. Pharmacol. 160 2010 2069 2084
73. L. Karamchand Lymphocyte mitochondrial depolarization and apoptosis in HIV-1-infected HAART patients J. Acquir. Immune Defic. Syndr. 48 2008 381 388
74. M.S. Jamaluddin Non-nucleoside reverse transcriptase inhibitor efavirenz increases monolayer permeability of human coronary artery endothelial cells Atherosclerosis 208 2010 104 111
75. K. El Hadri In vitro suppression of the lipogenic pathway by the nonnucleoside reverse transcriptase inhibitor efavirenz in 3T3 and human preadipocytes or adipocytes J. Biol. Chem. 279 2004 15130 15141 (Pubitemid 38618908)
76. J.M. Gallego-Escuredo Differential effects of efavirenz and lopinavir/ritonavir on human adipocyte differentiation, gene expression and release of adipokines and pro-inflammatory cytokines Curr. HIV Res. 8 2010 545 553
77. N. Apostolova Compromising mitochondrial function with the antiretroviral drug efavirenz induces cell survival-promoting autophagy Hepatology 54 2011 1009 1019
78. A. Maagaard Mitochondrial (mt)DNA changes in tissue may not be reflected by depletion of mtDNA in peripheral blood mononuclear cells in HIV-infected patients Antivir. Ther. 11 2006 601 608 (Pubitemid 44304038)
79. A. Maagaard Distinct mechanisms for mitochondrial DNA loss in T and B lymphocytes from HIV-infected patients exposed to nucleoside reverse-transcriptase inhibitors and those naive to antiretroviral treatment J. Infect. Dis. 198 2008 1474 1481
80. T.N. Kakuda Pharmacology of nucleoside and nucleotide reverse transcriptase inhibitor-induced mitochondrial toxicity Clin. Ther. 22 2000 685 708 (Pubitemid 30451995)
81. D. Nolan Mitochondrial DNA depletion and morphologic changes in adipocytes associated with nucleoside reverse transcriptase inhibitor therapy AIDS 17 2003 1329 1338 (Pubitemid 36819847)
82. T. Pulkes, and M.G. Hanna Human mitochondrial DNA diseases Adv. Drug Deliv. Rev. 49 2001 27 43 (Pubitemid 32493798)